Dispatches from HIE 2010

EFSA CLA rejection stalls business development

By Shane Starling

- Last updated on GMT

Related tags: Efsa health claim, Obesity, Nutrition

Lipid Nutrition global group manager in marketing, John Kurstjens, is “a little bit disappointed” about the recent EFSA health claim opinion on CLA which included a range of claim dismissals but remained strangely silent about the claim that matters most to CLA players – body fat reduction.

‘We don’t know the reason for that,” ​Kurstjens said of the rejected article 13.1 dossier that proposed body weight, body mass, insulin sensitivity, antioxidant and immunity claims.

“Certainly it has some effect on our business. Companies are really waiting to start up projects to develop new products for the market and waiting for the positive opinion of the EFSA. But still there are a lot of opportunities to use claims for CLA in the market.”

As with the other major player in the conjugated linoleic acid sector, Cognis, Lipid Nutrition is preparing an article 13.5 submission that will focus purely on body fat reduction it hopes to deliver to EFSA’s Parma, Italy base by year’s end.

“By mid-2011 we expect a positive opinion about it.”

EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) CLA opinion can be found here.

NutraIngredients health claims 2010

These matters and more will be discussed at the second NutraIngredients Health Claims 2010 conference to be held in Brussels on December 1. The conference will deconstruct the latest article 13.1 claim opinions, hear first-hand experience from players like Kellogg’s, outline regulation-coping marketing strategies, and feature comparison with the US claims system from leading industry figure, Dr Andrew Shao.

Related news

Show more

Related products

show more

Weight Management – New published clinical study

Weight Management – New published clinical study

Fytexia® | 20-Apr-2020 | Technical / White Paper

The benefits of Sinetrol on body composition have been supported by a new independent study on 86 South-Korean subjects. Data have been published this...

BERGAVIT™40:THE INNOVATION FOR CHOLESTEROL CONTROL

BERGAVIT™40:THE INNOVATION FOR CHOLESTEROL CONTROL

BIONAP Srl | 13-Apr-2020 | Product Brochure

THE INNOVATION AT BIONAP’S LABORATORIES NEVER STOP. BERGAVIT™ is able to reduce and control plasmatic “bad lipid” levels (total cholesterol, LDL and triglycerides)...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars